Griseofulvin compound and pharmaceutical use thereof
US-11993593-B2 · May 28, 2024 · US
HNF4-α antagonist and use thereof
US9795586B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9795586-B2 |
| Application number | US-201715464178-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 20, 2017 |
| Priority date | Jan 5, 2015 |
| Publication date | Oct 24, 2017 |
| Grant date | Oct 24, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Provided is a hepatocyte nuclear factor 4 alpha (HNF4-α) antagonist and a use thereof. The HNF4-α antagonist selected in the present invention was confirmed to specifically bind to the ligand binding domain of HNF4-α, thereby inhibiting the activity of HNF4-α. The HNF4-α antagonist of the present invention can significantly reduce the expression of Wnt5a in a specific manner compared to that of the conventional known HNF4-α antagonists, and can also inhibit the growth of gastric cancer cells. Therefore, the HNF4-α antagonist of the present invention can not only be used as a pharmaceutical composition or a health functional food for preventing and treating cancer but can also be applied to a composition for treating or preventing diseases occurring due to the overexpression of HNF4-α.
First claim
Opening claim text (preview).
What is claimed is: 1. A method for inhibiting activity of hepatocyte nuclear factor 4 alpha (HNF4-α) comprising administering an effective amount of a HNF4-α antagonist comprising a compound of the following Formula 1 or salts thereof to a subject in need of inhibition of HNF4-α activity: wherein R 1 to R 5 are each independently a hydrogen atom (H), a nitro group (NO 2 ), a halogen atom, a C 1-6 alkyl group substituted with one to six identical or different halogen atoms, or a C 1-6 alkyl group. 2. The method of claim 1 , wherein the compound of the Formula 1 is defined by the following Formula 3: 3. A method for treating gastric cancer comprising administering an effective amount of a hepatocyte nuclear factor 4 alpha (HNF4-α) antagonist comprising a compound of the following Formula 3 or salts thereof to a subject in need of gastric cancer treatment:
Assignees
Inventors
Classifications
- A61K31/343Primary
condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone · CPC title
having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole · CPC title
having five-membered rings · CPC title
Antineoplastic agents · CPC title
Coumarins, e.g. psoralen · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9795586B2 cover?
- Provided is a hepatocyte nuclear factor 4 alpha (HNF4-α) antagonist and a use thereof. The HNF4-α antagonist selected in the present invention was confirmed to specifically bind to the ligand binding domain of HNF4-α, thereby inhibiting the activity of HNF4-α. The HNF4-α antagonist of the present invention can significantly reduce the expression of Wnt5a in a specific manner compared to that of…
- Who is the assignee on this patent?
- Nat Cancer Ct
- What technology area does this patent fall under?
- Primary CPC classification A61K31/343. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Oct 24 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).